- Home
- LBTYB vs ICUI Comparison
LBTYB vs ICUI Comparison
Compare LBTYB & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | ICUI |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.6B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | ICUI |
|---|---|---|
| Price | $11.20 | $156.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $169.00 |
| AVG Volume (30 Days) | 5.1K | ★ 269.5K |
| Earning Date | 02-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | $4.46 |
| P/E Ratio | ★ N/A | $127.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.00 | $107.02 |
| 52 Week High | $29.01 | $162.85 |
Technical Indicators
Market Signals| Indicator | LBTYB | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 55.54 |
| Support Level | $10.02 | $139.88 |
| Resistance Level | $11.92 | $161.30 |
| Average True Range (ATR) | 1.22 | 4.52 |
| MACD | 0.02 | -0.84 |
| Stochastic Oscillator | 16.67 | 39.41 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.